See more : Elopak ASA (ELPKF) Income Statement Analysis – Financial Results
Complete financial analysis of PAO Group, Inc. (PAOG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAO Group, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Suzuyo Shinwart Corporation (9360.T) Income Statement Analysis – Financial Results
- Seeing Machines Limited (SEEMF) Income Statement Analysis – Financial Results
- First Republic Corporation of America (The) (FRPC) Income Statement Analysis – Financial Results
- Nova Leap Health Corp. (NLH.V) Income Statement Analysis – Financial Results
- MakeMyTrip Limited (MMYT) Income Statement Analysis – Financial Results
PAO Group, Inc. (PAOG)
About PAO Group, Inc.
PAO Group, Inc. focuses on alternative patient care treatments. The company, through its subsidiaries, engages in the development, sale, and distribution of premium medical cannabis products for treatment of chronic and terminal patients. The company is headquartered in Sandusky, Ohio.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 287.82K |
Cost of Revenue | 0.00 | 2.74K | 1.80K | 0.00 | 0.00 | 250.12K |
Gross Profit | 0.00 | -2.74K | -1.80K | 0.00 | 0.00 | 37.70K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 13.10% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 45.42K | 185.81K | 340.32K | 14.31K | 72.86K | 244.43K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.13K | 0.00 |
Operating Expenses | 45.42K | 185.81K | 340.32K | 14.31K | 76.99K | 244.43K |
Cost & Expenses | 45.42K | 188.55K | 342.12K | 14.31K | 76.98K | 494.55K |
Interest Income | 0.00 | 0.00 | 97.53K | 0.00 | 0.00 | 0.00 |
Interest Expense | 57.46K | 62.61K | 55.72K | 35.89K | 58.53K | 103.76K |
Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 161.14K |
EBITDA | 292.96K | -188.55K | -244.59K | -14.31K | 1.20M | -206.73K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -71.83% |
Operating Income | -45.42K | -188.55K | -342.12K | -14.31K | -76.99K | -206.73K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -71.83% |
Total Other Income/Expenses | 280.93K | -62.61K | 41.81K | -37.24K | 1.22M | -103.76K |
Income Before Tax | 235.51K | -251.16K | -300.30K | -51.55K | 1.14M | -310.49K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -107.88% |
Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | -161.14K |
Net Income | 235.51K | -251.16K | -300.30K | -51.55K | 1.14M | -310.49K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -107.88% |
EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 1.91B | 1.91B | 1.91B | 1.40B | 914.18M | 815.18M |
Weighted Avg Shares Out (Dil) | 1.91B | 1.91B | 1.91B | 1.40B | 914.18M | 815.18M |
PURA and PAOG CBD Nutraceutical Collaboration Highlighted In 420 Update Tomorrow
PURA and PAOG On Track To Launch CBD Product Line For $40 Billion Women's Health Market
PURA and PAOG To Launch CBD Product Line Next Month For $40 Billion Women's Health Market
PURA and PAOG Plan Sneak Peek Of CBD Nutraceutical Product Line For $17 Billion Market Opportunity
PURA and PAOG Plan Joint CBD Nutraceutical Product Line Launch Next Month
Why Russian Stock Mechel PAO Soared Today
PURA and PAOG Announce CBD IP Deal In Conjunction With New CBD Infused Product Developments
PURA and PAOG Confirm CBD IP Deal Schedule To Close Friday
PURA and PAOG Look To Tissue Culture Technology For Pharma Cannabis Cultivation
PURA and PAOG Partner With UCASU in Cannabis Real Estate Deal
Source: https://incomestatements.info
Category: Stock Reports